Search

Your search keyword '"Vauchier, Charles"' showing total 12 results
Start Over Author "Vauchier, Charles"
12 results on '"Vauchier, Charles"'

1. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study

Author

Fotia, Giuseppe, Saieva, Calogero, Lee-Ying, Richard, Patrikidou, Anna, Nuzzo, Pier Vitale, Zanardi, Elisa, Rossetti, Sabrina, Davidsohn, Matthew, Eid, Marc, El Zarif, Talal, McClure, Heather, Spinelli, Gian Paolo, Damassi, Alessandra, Murianni, Veronica, Vauchier, Charles, Oliveira, Thiago Martins, Malgeri, Andrea, Modesti, Mikol, Mestre, Ricardo Pereira, Valenca, Loana, Ravi, Praful, Santini, Daniele, Pignata, Sandro, De Giorgi, Ugo, Sweeney, Christopher, Heng, Daniel, Procopio, Giuseppe, Russo, Antonio, and Francini, Edoardo

Published
2024
Full Text
View/download PDF

2. Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study

Author

Baudry, Edwige, Naoun, Natacha, Auclin, Edouard, Saldana, Carolina, Barthelemy, Philippe, Geoffrois, Lionnel, Thibault, Constance, de Vries-Brilland, Manon, Borchiellini, Delphine, Maillet, Denis, Hirsch, Laure, Vauchier, Charles, Carril-Ajuria, Lucia, Colomba, Emeline, Bernard-Tessier, Alice, Escudier, Bernard, Flippot, Ronan, and Albigès, Laurence

Published
2023
Full Text
View/download PDF

3. Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Author

Nuzzo, Pier Vitale, primary, Ravera, Francesco, additional, Saieva, Calogero, additional, Zanardi, Elisa, additional, Fotia, Giuseppe, additional, Malgeri, Andrea, additional, Rossetti, Sabrina, additional, Valença, Loana Bueno, additional, Oliveira, Thiago Martins, additional, Vauchier, Charles, additional, Pereira Mestre, Ricardo, additional, Modesti, Mikol, additional, Patrikidou, Anna, additional, Pignata, Sandro, additional, Procopio, Giuseppe, additional, Fornarini, Giuseppe, additional, De Giorgi, Ugo, additional, Russo, Antonio, additional, and Francini, Edoardo, additional

Published
2023
Full Text
View/download PDF

4. sj-doc-1-tam-10.1177_17588359231156147 – Supplemental material for Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Author

Nuzzo, Pier Vitale, Ravera, Francesco, Saieva, Calogero, Zanardi, Elisa, Fotia, Giuseppe, Malgeri, Andrea, Rossetti, Sabrina, Valença, Loana Bueno, Oliveira, Thiago Martins, Vauchier, Charles, Pereira Mestre, Ricardo, Modesti, Mikol, Patrikidou, Anna, Pignata, Sandro, Procopio, Giuseppe, Fornarini, Giuseppe, De Giorgi, Ugo, Russo, Antonio, and Francini, Edoardo

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-doc-1-tam-10.1177_17588359231156147 for Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer by Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Bueno Valença, Thiago Martins Oliveira, Charles Vauchier, Ricardo Pereira Mestre, Mikol Modesti, Anna Patrikidou, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo and Edoardo Francini in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

5. Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study

Author

Guezour, Nadia, primary, Soussi, Ghassen, additional, Brosseau, Solenn, additional, Abbar, Baptiste, additional, Naltet, Charles, additional, Vauchier, Charles, additional, Poté, Nicolas, additional, Hachon, Lorry, additional, Namour, Céline, additional, Khalil, Antoine, additional, Trédaniel, Jean, additional, Zalcman, Gérard, additional, and Gounant, Valérie, additional

Published
2022
Full Text
View/download PDF

6. REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study

Author

Vauchier, Charles, primary, Auclin, Edouard, additional, Barthélémy, Philippe, additional, Carril-Ajuria, Lucia, additional, Ryckewaert, Thomas, additional, Borchiellini, Delphine, additional, Castel-Ajgal, Zahra, additional, Bennamoun, Mostefa, additional, Campedel, Luca, additional, Thiery-Vuillemin, Antoine, additional, Coquan, Elodie, additional, Crouzet, Laurence, additional, Berdah, Jean-François, additional, Chevreau, Christine, additional, Ratta, Raffaele, additional, Fléchon, Aude, additional, Lefort, Felix, additional, Albiges, Laurence, additional, Gross-Goupil, Marine, additional, Vano, Yann-Alexandre, additional, Thibault, Constance, additional, and Oudard, Stéphane, additional

Published
2022
Full Text
View/download PDF

8. Rechallenge of nivolumab in metastatic renal cell carcinoma, an ambispective multicenter study (RENIVO).

Author

Vauchier, Charles, primary, Auclin, Edouard, additional, Barthelemy, Philippe, additional, Carril, Lucia, additional, Ryckewaert, Thomas, additional, Borchiellini, Delphine, additional, Ajgal, Zahra, additional, Bennamoun, Mostefa, additional, Campedel, Luca, additional, Thiery-Vuillemin, Antoine, additional, Coquan, Elodie, additional, Crouzet, Laurence, additional, Berdah, Jean Francois, additional, Chevreau, Christine, additional, Ratta, Raffaele, additional, Flechon, Aude, additional, Lefort, Felix, additional, Gross-Goupil, Marine, additional, Thibault, Constance, additional, and Oudard, Stephane, additional

Published
2021
Full Text
View/download PDF

9. Enjeux et écueils des thérapies ciblées orales en pratique clinique quotidienne : 5e journée de pharmacologie des anti-tumoraux

Author

Zaibet, Sonia, primary, Vauchier, Charles, additional, Khoudour, Nihel, additional, Roulleaux Dugage, Matthieu, additional, Korb-Savoldelli, Virginie, additional, Alexandre, Jérôme, additional, Blanchet, Benoit, additional, Goldwasser, François, additional, Thomas-Schoemann, Audrey, additional, and Bellesoeur, Audrey, additional

Published
2018
Full Text
View/download PDF

10. Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial

Author

Oudard, Stephane, Tran, Yohann, Helissey, Carole, Vauchier, Charles, Ratta, Raffaele, Bennamoun, Mostefa, Voog, Eric, Hasbini, Ali, Thiery-Vuillemin, Antoine, Aldabbagh, Kais, Saldana, Carolina, Sevin, Emmanuel, Amela, Eric, Von Amsberg, Gunhild, Houede, Nadine, Besson, Dominique, Feyerabend, Susan, Boegemann, Martin, Pfister, David, Schostak, Martin, Huillard, Olivier, Di Fiore, Frederic, Quivy, Amandine, Vernerey, Dewi, Falcoz, Antoine, Youcef-Ali, Karima, Kotti, Salma, Lepicard, Eve M., and Barthelemy, Philippe

Abstract

Little is known about the impact of biweekly cabazitaxel 16 mg/m2(CBZ q2w) plus prophylactic granulocyte colony-stimulating factor (G-CSF) on pain and health-related quality of life (HRQoL) compared with the standard regimen (25 mg/m2CBZ triweekly) plus G-CSF, in older men with metastatic castration-resistant prostate cancer (mCRPC). In this prospective, randomized phase 3 trial, CBZ q2w plus G-CSF maintained HRQoL and did not deteriorate pain intensity in mCRPC patients who had previously progressed under docetaxel and at least one novel androgen receptor pathway inhibitor. CBZ q2w plus G-CSF could increase the number of patients with mCRPC eligible for chemotherapy and enable a more patient-centered approach.

Published
2024
Full Text
View/download PDF

11. Enjeux et écueils des thérapies ciblées orales en pratique clinique quotidienne : 5ejournée de pharmacologie des anti-tumoraux

Author

Zaibet, Sonia, Vauchier, Charles, Khoudour, Nihel, Roulleaux Dugage, Matthieu, Korb-Savoldelli, Virginie, Alexandre, Jérôme, Blanchet, Benoit, Goldwasser, François, Thomas-Schoemann, Audrey, and Bellesoeur, Audrey

Abstract

Les thérapies ciblées orales sont une classe de médicaments anti-tumoraux en pleine expansion. À l’issue d’essais cliniques menés sur des populations sélectionnées, ces molécules sont approuvées le plus souvent selon une posologie unique. Pourtant, elles présentent une grande variabilité pharmacocinétique inter et intra-individuelle, et un index thérapeutique étroit qui peuvent rendre leur prescription à risque chez les individus non sélectionnés de la pratique clinique quotidienne. La multiplication des thérapies ciblées à notre disposition doit conduire à prendre en compte de nouveaux enjeux qui concernent notamment la prescription chez les patients hors-norme, et les modalités d’adaptation posologique pour tenir compte des facteurs de vulnérabilité de ces individus, et parvenir à une prescription sécurisée et individualisée. D’autre part, nombre de ces thérapies sont métabolisées par le CYP 3A4, en faisant des traitements à risque élevé d’interactions médicamenteuses, non seulement avec les produits de la pharmacopée traditionnelle mais aussi avec les médecines alternatives et complémentaires, elles aussi en pleine expansion, mais souvent mal connues de l’oncologue. Enfin, la voie orale soulève la question de l’observance, dont l’évaluation doit désormais s’intégrer à la prise en charge.

Published
2018
Full Text
View/download PDF

12. [Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].

Author

Zaibet S, Vauchier C, Khoudour N, Roulleaux Dugage M, Korb-Savoldelli V, Alexandre J, Blanchet B, Goldwasser F, Thomas-Schoemann A, and Bellesoeur A

Subjects
Administration, Oral, Antineoplastic Agents adverse effects, Drug Interactions, Humans, Hypertension chemically induced, Molecular Targeted Therapy methods, Precision Medicine trends, Protein Kinase Inhibitors therapeutic use, Antineoplastic Agents administration & dosage, Neoplasms drug therapy, Precision Medicine methods
Abstract

Oral targeted therapies are a growing class of medication. After clinical trials conducted on a selected population, these molecules are usually approved at a fixed dose. However, oral tyrosine kinase inhibitors are characterized by a large intra and inter-individual pharmacokinetic variability, and a narrow therapeutic index. Hence, their prescription is hazardous and unsafe in non-selected people from daily clinical practice. The increasing number of available targeted therapies point out new challenges. These challenges should especially concern prescription for out of the ordinary patients, rules for dose adjustment according to factors of frailty. The ultimate goal is to ensure a safe and individualized prescription. Moreover, many of these molecules are metabolized by the CYP3A4, leading to a serious risk of drug interaction. These interactions might involve not only conventional medicine but also alternative and complementary medicines. These latter are more and more common but oncologists often lack experience about them. Finally, the oral route raises the issues of adherence, and the question of its assessment should now become a permanent part of patients care., (Copyright © 2018.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results